Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC): "today’s move seems like an over-reaction"
Tweet Send to a Friend
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on ORIC Pharmaceuticals (NASDAQ: ORIC)The analyst commented, "Depending on the event ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
